Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: Diagnosis and management

Current Opinion in Cardiology

Volumn 27, Issue 3, 2012, Pages 281-287

  Ohara, Takahiro ^a   Ohte, Nobuyuki ^b   Little, William C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

exercise induced pulmonary hypertension; heart failure with preserved ejection fraction; phosphodiesterase 5 inhibitor; pulmonary hypertension; pulmonary vascular resistance

Indexed keywords

BOSENTAN; DARUSENTAN; PROSTACYCLIN; SILDENAFIL;

EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION; VENOUS PRESSURE;

BLOOD PRESSURE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; PULMONARY VEINS; STROKE VOLUME; VASOCONSTRICTION; VENTRICULAR FUNCTION, LEFT;

EID: 84859902635     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835220b1     Document Type: Review

References (44)

1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259. (Pubitemid 44079340)
2. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296:2209-2216. (Pubitemid 44708051)
3. Gaasch WH, Delorey DE, Kueffer FJ, et al. Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol 2009; 104:1413-1415.
4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM preserved trial. Lancet 2003; 362:777-781. (Pubitemid 37093918)
5. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345. (Pubitemid 44453578)
6. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006; 114:397-403. (Pubitemid 44264821)
7. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
8. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest 2007; 131:94-100. (Pubitemid 46122979)
9. Lewis GD, Shah RV, Pappagianopolas PP, et al. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circulation 2008; 1:227-233.
10. Berkowitz R, Alhaj E, Manchikalapudi RB, et al. Determinants of right ventricular failure in patients admitted with acute left heart failure. Congest Heart Fail 2010; 16:243-248.
11. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118:1433-1441.
12. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183-188. (Pubitemid 32051736)
13. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S43-S54.
14. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619.
15. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007; 28:233-241. (Pubitemid 46350735)
16. Boilson BA, Schirger JA, Borlaug BA. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution. Eur J Heart Fail 2010; 12:89-93.
17. Chatterjee NA, Lewis GD. What is the prognostic significance of pulmonary hypertension in heart failure? Circulation 2011 4 541-545.
18. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550. (Pubitemid 47614269)
19. Gaasch WH, Little WC. Assessment of left ventricular diastolic function and recognition of diastolic heart failure. Circulation 2007; 116:591-593. (Pubitemid 47356343)
20. Lam C, Roger V, Rodeheffer R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community based study. J Am Coll Cardiol 2009; 53:1119-1126.
21. Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106:284-286.
22. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4:257-265.
23. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
24. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223. (Pubitemid 17137857)
25. Janda S, Shahidi N, Gin K, et al. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97:612-622.
26. D'Andrea A, Riegler L, Golia E, et al. Range of right heart measurements in top-level athletes: the training impact. Int J Cardiol 2011. [Epub ahead of print]
27. D'Andrea A, Naeije R, D'Alto M, et al. Range in pulmonary artery systolic pressure among highly trained athletes. Chest 2011; 139:788-794.
28. Maeder MT, Thompson BR, Brunner-La Rocca HP, et al. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 2010; 56:855-863.
29. Maeder MT, Karapanagiotidis S, Dewar EM, et al. Accuracy of Doppler echocardiography to estimate key hemodynamic variables in subjects with normal left ventricular ejection fraction. J Card Fail 2011; 17:405-412.
30. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:268-276.
31. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. Cardiovasc Ultrasound 2010; 8:21.
32. Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41:1021-1027. (Pubitemid 36315548)
33. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588-595.
34. Shim CY, Kim SA, Choi D, et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart 2011; 97:1417-1424.
35. Bossone E, Rubenfire M, Bach DS, et al. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999; 33:1662-1666.
36. Tolle JJ, Waxman AB, Van Horn TL, et al. Exercise-induced pulmonary arterial hypertension. Circulation 2008; 118:2183-2189.
37. Fowler RM, Maiorana AJ, Jenkins SC, et al. Implications of exercise-induced pulmonary arterial hypertension. Med Sci Sports Exerc 2011; 43:983-989.
38. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44-54. (Pubitemid 27329022)
39. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on leftventricular remodeling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebocontrolled trial. Lancet 2004; 364:347-354.
40. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999; 1:197-200. (Pubitemid 30186712)
41. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 2002 8 124-127.
42. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124:164-174.
43. Waxman AB. Pulmonary hypertension in heart failure with preserved ejection fraction. Circulation 2011; 124:133-135.
44. Yin J, Kukucka M, Hoffmann J, et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011; 4:198-206.